Feb. 13 at 8:46 PM
$MNKD Cipla introduced Afrezza to India to address the significant, unmet need for needle-free, rapid-acting mealtime insulin for diabetes management. It offers a convenient, inhalable alternative to traditional injections, reducing pain, anxiety, and social stigma associated with injections while improving glycemic control in a country with over 101 million people living with diabetes.
Key reasons for introducing Afrezza in India include:
Needle-Free Convenience: It eliminates the discomfort and fear associated with daily insulin injections.
Rapid Action: It starts working in as little as 12 minutes, mimicking the body's natural insulin response after meals.
Patient Compliance: It reduces behavioral barriers to treatment, such as stigma, improving adherence to therapy.
